A 46-year-old male with COPD on Seretide is now prescribed a long-acting muscarinic antagonist due to persistent breathlessness. Which drug is he most likely prescribed?

A 46-year-old male with COPD on Seretide is now prescribed a long-acting muscarinic antagonist due to persistent breathlessness. Which drug is he most likely prescribed?

• A. Tiotropium
• B. Ipratropium
• C. Aclidinium
• D. Umeclidinium

Answer: (A)

In COPD, long-acting muscarinic antagonists provide sustained bronchodilation by blocking M3 receptors in airway smooth muscle, helping to reduce breathlessness and improve exercise tolerance. When symptoms persist despite an ICS/LABA (as in this patient on Seretide), adding a LAMA is a common next step to further improve airflow. Tiotropium is the classic and most established LAMA for maintenance therapy in COPD. It has a long track record of improving dyspnea, reducing rescue inhaler use, and decreasing exacerbations, with convenient once-daily dosing that fits long-acting maintenance treatment. Given these advantages and its widespread use as the first-choice LAMA, it is the most likely prescription in this scenario. Ipratropium is a short-acting antimuscarinic and not designed for maintenance therapy. Aclidinium and umeclidinium are also LAMAs, but tiotropium remains the most familiar, widely studied, and guideline-supported option as the initial LAMA add-on in patients continuing to have breathlessness on ICS/LABA.

In COPD, long-acting muscarinic antagonists provide sustained bronchodilation by blocking M3 receptors in airway smooth muscle, helping to reduce breathlessness and improve exercise tolerance. When symptoms persist despite an ICS/LABA (as in this patient on Seretide), adding a LAMA is a common next step to further improve airflow.

Tiotropium is the classic and most established LAMA for maintenance therapy in COPD. It has a long track record of improving dyspnea, reducing rescue inhaler use, and decreasing exacerbations, with convenient once-daily dosing that fits long-acting maintenance treatment. Given these advantages and its widespread use as the first-choice LAMA, it is the most likely prescription in this scenario.

Ipratropium is a short-acting antimuscarinic and not designed for maintenance therapy. Aclidinium and umeclidinium are also LAMAs, but tiotropium remains the most familiar, widely studied, and guideline-supported option as the initial LAMA add-on in patients continuing to have breathlessness on ICS/LABA.